Sector Expert: Pnina Fishman

Can-Fite BioPharma Ltd.

Image: Pnina Fishman

Pnina Fishman is the scientific founder of Can-Fite BioPharma Ltd. and was previously a professor of life sciences and headed the Laboratory of Clinical and Tumor Immunology at the Felsenstein Medical Research Institute, Rabin Medical Center. Prof. Fishman is an accomplished scientist and has authored or coauthored more than 150 publications and presented the findings of her research at many major scientific meetings. Her scientific work was the foundation on which Can-Fite was built. This scientific work has gained recognition as one of the leading approaches for new generation therapies for cancer and other diseases. Her past managerial experience included seven years as CEO of Mor Research Application (MRA), a company that was in charge of the commercialization of intellectual property from all hospitals and research centers of Clalit Health Services, the largest healthcare provider in Israel, and was also the first clinical CRO in Israel. She was also involved in the establishment and served on the board of directors of several life sciences technology start-ups.



Recent Interviews

One Target with Multiple Shots on Goal: Can-Fite BioPharma CEO Pnina Fishman (3/4/15)
moleculebeaker580

The target is a single receptor found only on abnormal cellsócancer cells and cells responsible for inflammatory diseases such as psoriasis. The weapon is a platform technology developed by Can-Fite BioPharma Ltd. under the guidance of Scientific Founder and CEO Pnina Fishman and her team. The company is developing an arsenal of therapies approaching the final stages of clinical trials, and in this interview with The Life Sciences Report, Fishman describes the catalysts and candidates that make Can-Fite a strong bet for investors.



Due to permission requirements, not all quotes are shown.